CLINICAL_TRIALS
trial_result
· 2021-01-05
Clinical Trial Update: A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma [Phase 2]
Summary
Phase II study of MEK162 as a single agent in patients with BRAF or NRAS mutant metastatic melanoma has completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: BRAF or NRAS Mutant Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2021-01-05